Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na+, K+ATPase activity in sciatic nerves of streptozotocin-induced diabetic rats

Phytomedicine

Volumn 5, Issue 2, 1998, Pages 121-127

  Shin, K H ^a   Lim, S S ^a   Kim, D K ^a  

^a Seoul National University   (South Korea)

Author keywords

Byakangelicin; Furanocoumarin; Galactitol; Galactosemic cataract; Myo inositol; Na+K+ATPase; Sciatic nerve; Sorbitol; Streptozotocin induced diabetes

Indexed keywords

ANGELICA DAHURICA; ANIMALIA;

EID: 2942512583     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0944-7113(98)80008-1     Document Type: Article

References (30)

1. Aida, K., Tawata, M., Shindo, H., Onaya, T., Sasaki, H., Yamaguchi, T., Chin, M. and Mitsuhashi, H.: Isoliquirigenin; A new aldose reductase inhibitor from Glycyrrhizae Radix. Planta Med 56: 255 - 258,1990.
2. Beyer-Mears, A., Ku, L. and Cohen, M.: Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil. Diabetes 33: 604 - 607,1984.
3. Beyer-Mear, A. and Cruz, E.: Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor. Diabetes 34: 15-21,1985.
4. Dvornic, D., Simard-Duguesne, N., Krami, M., Sestanj, K., Gabbay, K. H., Kinoshita, J. H., Varma, S. D. and Merola, L. O.: Polyol accumulation in galactosemic and diabetic rats, Control by an aldose reductase inhibitor. Science 182: 1146-1147,1973.
5. Finegold, D., Lattimer, S. A., Nolle, S., Bernstein, M. and Greene, D. A.: Polyol pathway activity and myo-inositol metabolism: a suggested relationship in the pathogenesis of diabetic neuropathy. Diabetes 32: 988 - 992, 1983.
6. Gillon, K. R. W. and Hawthorne, J. N.: Sorbitol, inositol and nerve conduction in diabetes. Life Sci. 32: 1943-1947, 1983.
7. Greene, D. A. and Lattimer, S. A.: Action of sorbinil in diabetic peripheral nerve. Relationship of polyol pathway inhibition to a myo-inositol-mediated defect in sodium-potassium ATPase activity. Diabetes 33: 712 -716, 1984.
8. Greene, D. A. and Lattimer, S. A.: Impaired rat sciatic nerve sodium-potassium ATPase in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation. J. Clin. Invest. 72: 1058 -1063,1983.
9. Greene, D. A., Sima, A. AF, Stevens, M. J., Feldman, E. L. and Lattimer, S. A.: Complications: Neuropathy, pathogenetic considerations. Diabetes Care 15:1902 -1925, 1992.
10. Greene, D. A., Lattimer, S. A. and Sima, A. AF: Sorbitol, phosphoinositides and sodium-potassium ATPase in the pathogenesis of diabetic complications. N. Engl. J. Med. 316:599-606,1987.
11. Handelsman, D. J. and Turtle, J. R.: Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 30: 459-464,1981.
12. Hayman, S., Lou, M. F., Merola, L. O. and Kinoshita, J. H.: Aldose reductase activity in the lens and other tissues. Biochim. Biophys. Acta 128: 474-482, 1966.
13. Inakai, K., Miwa, I., Yashiro, T. and Okuda, J.: Inhibition of aldose reductase from rat and bovine lenses by hydantoin derivatives. Chem. Pharm. Bull. 30: 3244 - 3254, 1982.
14. Jacques, P. E, Chylack, L. T. Jr., Mcgandy, R. B. and Hartz, S. C.: Antioxidant status in persons with and without senile cataract. Arch. Ophthalmol. 106: 337-340, 1988.
15. Kato, K., Nakayama, K., Mizota, M., Miwa, I. and Okuda, J.: Properties of novel aldose reductase inhibitors, M 16209 and M 16287, in comparison with known inhibitors, ONO-2235 and sorbinil. Chem. Pharm. Bull. 39: 1540-1545,1991.
16. Kinoshita, J. H.: Mechanisms initiating cataract formation. Invest. Ophthalmol. 13: 713 -723, 1974.
17. Nakagaki, M., Koga, N. and Iwata, S.: Effect of catalin and analogous phenoxazone compounds on lens proteins. Acta Soc. Ophthalmol. Jap. 69: 285 - 292, 1965.
18. Pirie, A. and Van Heyningen, R.: The effect of diabetes on the content of the sorbitol, glucose, fructose and inositol in the human lens. Exp. Eye Res. 3: 124 -131,1964.
19. Poulsom, R.: Comparison of aldose reductase inhibitors in vitro. Effects of enzyme purification and substrate type. Biochcin. Pharmacol. 36: 1577-1581, 1987.
20. Raskin, P. and Rosenstock, J.: Aldose reductase inhibitors and diabetic complications. Am. J. Med 83: 298 - 306, 1987.
21. Shimizu, M., Ito, T., Terashima, S., Hayashi, T., Arisawa, M., Morita, N., Kurokawa, S., Ito, K. and Hashimoto, Y.: Inhibition of lens aldose reductase by flavonoids. Phytochemistry 23: 1885 -1888, 1984.
22. Shin, K. H., Woo, W. S., Moon, K. H. and Yoo, S. J.: Effects of naturally occurring furanocoumarins on lipid peroxidation and carbon tetrachloride induced hepatotoxicity in mice. Arch. Pharm. Res. 16:13 -17, 1993.
23. Shin, K. H., Chung, M. S., Chae, Y. J., Yoon, K. Y. and Cho, T. S.: A survey for aldose reductase inhibition of some herbal medicines. Fitoterapia 64: 130 -133, 1993.
24. Shin, K. H., Chung, M. S. and Cho, T. S.: Effects of furanocoumarins from Angelica dahurica on aldose reductase and galactosemic cataract formation in rats. Arch Pharm. Res. 17:331-336,1994.
25. Shin, K. H., Kang, S. S., Kim, H. J. and Shin, S. W.: Isolation of an aldose reductase inhibitor from the fruits of Vitex rotnndifolia. Phytomedicine 1:145 -147,1994.
26. Shin, K. H., Kang, S. S., Seo, E. A. and Shin, S. W.: Isolation of aldose reductase inhibitors from the flowers of Chrysanthemum boreale. Arch. Pharm. Res. 18: 65 - 68,1995.
27. Simmons, D. A., Winegrad, A. I. and Martin, D. B.: Significance of tissue myo-inositol concentrations in metabolic regulation in nerve. Science 217: 848 - 851, 1982.
28. Terashima, H., Hama, K., Yamamoto, R., Tsuboshima, M., Kikkawa, R., Hatanaka, I. and Shigeta, Y.: Effects of a new aldose reductase inhibitor on various tissues in vitro. J. Pharm. Exp. Ther. 229: 226 - 230,1984.
29. Van Heyningen, R.: Formation of polyol by the lens of the rat with sugar cataract. Nature (London) 184: 194-196, 1959.
30. Ward, J. D. In Advances in Metabolic Disorders (Suppl. 2) ed by R. A. Camerini-Daralos and H. S. Cole, Academic Press, New York, p. 425 - 429, 1973.